BUZZ-China's WuXi XDC rises on robust results forecast
Reuters01-15
** WuXi XDC Cayman 2268.HK rises 4.4% to HK$30.75; set for a second straight session of gains
** Chinese antibody drug developer sees 2024 rev, net profit and adjusted net profit jumping more than 85%, 260% and 170% y/y, respectively, on demand from antibody drug conjugate and bioconjugate industries
** Profit margin improving on high utilisation rate of co's production facilities; faster ramp-up of production lines also increases operating efficiency
** Stock third biggest pct gainer on Hong Kong's healthcare index .HSCIH, which is down 0.7%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
